MEDPLUS Stock Overview
Engages in the retail trading of medicines and general items in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MEDPLUS from our risk checks.
My Notes
Capture your thoughts, links and company narrative
MedPlus Health Services Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹848.05 |
| 52 Week High | ₹875.65 |
| 52 Week Low | ₹598.60 |
| Beta | 0.69 |
| 1 Month Change | 14.79% |
| 3 Month Change | 27.03% |
| 1 Year Change | 16.72% |
| 3 Year Change | -21.19% |
| 5 Year Change | n/a |
| Change since IPO | -24.36% |
Recent News & Updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding MedPlus Health Services Limited's (NSE:MEDPLUS) Performance Completely
Dec 05
There Are Reasons To Feel Uneasy About MedPlus Health Services' (NSE:MEDPLUS) Returns On Capital
Aug 30Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding MedPlus Health Services Limited's (NSE:MEDPLUS) Performance Completely
Dec 05There Are Reasons To Feel Uneasy About MedPlus Health Services' (NSE:MEDPLUS) Returns On Capital
Aug 30Is Now The Time To Put MedPlus Health Services (NSE:MEDPLUS) On Your Watchlist?
Feb 03MedPlus Health Services (NSE:MEDPLUS) Will Want To Turn Around Its Return Trends
Dec 11A Look At The Intrinsic Value Of MedPlus Health Services Limited (NSE:MEDPLUS)
Oct 24The Returns On Capital At MedPlus Health Services (NSE:MEDPLUS) Don't Inspire Confidence
Jul 18Why Investors Shouldn't Be Surprised By MedPlus Health Services Limited's (NSE:MEDPLUS) P/S
Jun 22A Look At The Fair Value Of MedPlus Health Services Limited (NSE:MEDPLUS)
Apr 18MedPlus Health Services (NSE:MEDPLUS) Could Be Struggling To Allocate Capital
Feb 08₹1,177: That's What Analysts Think MedPlus Health Services Limited (NSE:MEDPLUS) Is Worth After Its Latest Results
Jun 03Shareholder Returns
| MEDPLUS | IN Consumer Retailing | IN Market | |
|---|---|---|---|
| 7D | -0.8% | -4.6% | -2.1% |
| 1Y | 16.7% | -8.6% | 22.5% |
Return vs Industry: MEDPLUS exceeded the Indian Consumer Retailing industry which returned -8.6% over the past year.
Return vs Market: MEDPLUS underperformed the Indian Market which returned 22.5% over the past year.
Price Volatility
| MEDPLUS volatility | |
|---|---|
| MEDPLUS Average Weekly Movement | 4.1% |
| Consumer Retailing Industry Average Movement | 6.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: MEDPLUS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MEDPLUS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 23,415 | Gangadi Reddy | www.medplusindia.com |
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, comprising medicines, vitamins, medical devices, and test kits; and offers consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. The company also provides wholesale cash and carry; diagnostic, pathological, and laboratory testing services, as well as engages in the contract manufacturing of private label pharmaceuticals.
MedPlus Health Services Limited Fundamentals Summary
| MEDPLUS fundamental statistics | |
|---|---|
| Market cap | ₹103.45b |
| Earnings (TTM) | ₹1.00b |
| Revenue (TTM) | ₹59.97b |
101.2x
P/E Ratio1.7x
P/S RatioIs MEDPLUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDPLUS income statement (TTM) | |
|---|---|
| Revenue | ₹59.97b |
| Cost of Revenue | ₹46.57b |
| Gross Profit | ₹13.40b |
| Other Expenses | ₹12.40b |
| Earnings | ₹1.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.38 |
| Gross Margin | 22.34% |
| Net Profit Margin | 1.67% |
| Debt/Equity Ratio | 0% |
How did MEDPLUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:38 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MedPlus Health Services Limited is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |